7. Merck - Top 15 R&D Budgets

Who: Merck

2006 Pipeline Budget: $5.3 billion (€3.62)

2007 Pipeline News: One of Merck's biggest pipeline hopes is anacetrapib, a drug designed to increase good cholesterol and decrease bad cholesterol. Sound familiar? That's because anacetrapib is a CTEP inhibitor--the same class of drug as Pfizer's failed torcetrapib. The drug, which is currently in Phase II, could tap into a $15 billion market.

In 2007 Merck received FDA approval of HIV drug Isentress, filed an NDA for Cordaptive (a cholesterol drug that combines a known ingredient with a new one that reduces the risk of flushing). The company also inked a billion-dollar pact for Ariad's cancer drug AP23573, which is in late-stage testing for metastatic sarcomas. And Sanofi-Aventis better get its act together with Acomplia, because Merck's obesity drug taranabant is in Phase III and could be up for FDA approval in 2008.

Pending Approval:
MK-0518 (raltegravir) - HIV
MK-0517 - chemotherapy-induced nausea and vomiting (approvable)

Phase III
MK-0524A - Atherosclerosis
MK-0524B - Atherosclerosis
MK-0364 (taranabant) - Obesity
MK-0974 - Migraine
MK-8669 - Cancer

Full Pipeline Site: Link

7. Merck - Top 15 R&D Budgets
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.